Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD and Safety of SHR4640 in Hepatic Impairment
NCT04305392Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruzinurad in gout and hyperuricemia (3 arms), sponsored by Hengrui. Primary endpoints: Peak Plasma Concentration at 72 hours and Area under the plasma concentration versus time curve at 72 hours. Status: unknown.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04305392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305392.